A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge

• Autors principals: Emin Taşkıran (Autor), Sevnaz Şahin (Autor), Sumru Savaş (Autor), Zeliha Fulden Saraç (Autor), Selahattin Fehmi Akçiçek (Autor)
• Format: Llibre
• Publicat: International Journal of Immunotherapy and Cancer Research - Peertechz Publications, 2021-10-08.
• Matèries: Case Report
• Accés en línia: Connect to this object online.

<p>Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages...